Adil Mariam, Ghori Dua, Anwar Eman, Shaukat Maryam, Malik Muhammad T H, Murtaza Dua A, Sumra Khadija A, Essani Rabia, Nizami Urooj, Khan Bakhtawer N, Abid Hunaina, Oduoye Malik Olatunde
Dow University of Health Sciences, Karachi, Pakistan.
Aga Khan University, Karachi, Pakistan.
Int J Surg. 2024 Dec 1;110(12):8073-8082. doi: 10.1097/JS9.0000000000002090.
Gastric cancer ranks as the fifth most frequently diagnosed cancer and the seventh most prevalent overall. The lifetime risk of developing gastric cancer is 1.87% for males and 0.79% for females worldwide.
This systematic review and meta-analysis aimed to determine whether extensive intraoperative peritoneal lavage (EIPL) provides short-term benefits or improved survival outcomes for patients undergoing gastrectomy.
A comprehensive search spanned PubMed, Embase, Cochrane Library, clinicaltrials.gov, and Web of Science, from their inception up to October 2023, adhering to predefined inclusion and exclusion criteria. The quality of the studies was analyzed using the Cochrane Collaboration Risk of Bias Tool. Data analysis was done using Review Manager 5.3, utilizing a random-effects model.
Our analysis incorporated seven randomized controlled trials with 2602 patients. The follow-up time for all outcomes varied from 30-60 months. For our primary outcomes, EIPL demonstrated a significant benefit over surgery alone in terms of recurrence (RR=0.73; 95% CI: 0.65-0.83, P <0.00001) and postoperative complications (RR=0.67; 95% CI: 0.51-0.87, P =0.003). For our secondary outcomes, postoperative hospital stay (MD=-0.35; 95% CI: -1.11 to 0.41; P =0.37), 3-year overall survival (OR=1.44; 95% CI: 0.84-2.47; P =0.19), 3-year disease-free survival (HR=0.93; 95% CI: 0.78-1.13; P =0.48), and time to first flatus (MD=-0.17; 95% CI: -0.35 to 0.01; P =0.06), no statistically significant differences were observed between the EIPL and control groups.
While there is a marginal difference in survival outcomes, EIPL holds promise in significantly reducing overall cancer recurrence and suggests an enhancement in postoperative recovery.
胃癌是全球第五大最常被诊断出的癌症,总体上是第七大常见癌症。全球男性患胃癌的终生风险为1.87%,女性为0.79%。
本系统评价和荟萃分析旨在确定广泛术中腹腔灌洗(EIPL)是否能为接受胃切除术的患者带来短期益处或改善生存结果。
从PubMed、Embase、Cochrane图书馆、clinicaltrials.gov和Web of Science创建之初到2023年10月进行全面检索,遵循预定义的纳入和排除标准。使用Cochrane协作偏倚风险工具分析研究质量。使用Review Manager 5.3进行数据分析,采用随机效应模型。
我们的分析纳入了7项随机对照试验,共2602例患者。所有结局的随访时间为30至60个月。对于我们的主要结局,EIPL在复发(RR = 0.73;95%CI:0.65 - 0.83,P < 0.00001)和术后并发症(RR = 0.67;95%CI:0.51 - 0.87,P = 0.003)方面显示出比单纯手术有显著益处。对于我们的次要结局,术后住院时间(MD = -0.35;95%CI:-1.11至0.41;P = 0.37)、3年总生存率(OR = 1.44;95%CI:0.84 - 2.47;P = 0.19)、3年无病生存率(HR = 0.93;95%CI:0.78 - 1.13;P = 0.48)和首次排气时间(MD = -0.17;95%CI:-0.35至0.01;P = 0.06),EIPL组和对照组之间未观察到统计学上的显著差异。
虽然在生存结果上存在微小差异,但EIPL有望显著降低总体癌症复发率,并表明术后恢复有所改善。